Michael Schwitter
Population pharmacokinetics of TLD-1, a novel liposomal doxorubicin, in a phase I trial.
Mc Laughlin A, Hess D, Michelet R, Colombo I, Haefliger S, Bastian S, Rabaglio-Poretti M, Schwitter M, Fischer S, Eckhardt K, Hayoz S, Kopp C, Klose M, Sessa C, Stathis A, Halbherr S, Huisinga W, Jörger M, Kloft C. Population pharmacokinetics of TLD-1, a novel liposomal doxorubicin, in a phase I trial. Cancer Chemother Pharmacol 2024; 94:349-360.
Jun 15, 2024Population pharmacokinetics of TLD-1, a novel liposomal doxorubicin, in a phase I trial.
Jun 15, 2024Cancer Chemother Pharmacol 2024; 94:349-360
Mc Laughlin Anna M, Hess Dagmar, Michelet Robin, Colombo Ilaria, Haefliger Simon, Bastian Sara, Rabaglio-Poretti Manuela, Schwitter Michael, Fischer Stefanie, Eckhardt Katrin, Hayoz Stefanie, Kopp Christoph, Klose Marian, Sessa Cristiana, Stathis Anastasios, Halbherr Stefan, Huisinga Wilhelm, Jörger Markus, Kloft Charlotte
TLD-1, a novel liposomal doxorubicin, in patients with advanced solid tumors: Dose escalation and expansion part of a multicenter open-label phase I trial (SAKK 65/16).
Colombo I, Koster K, Holer L, Haefliger S, Rabaglio-Poretti M, Bastian S, Schwitter M, Eckhardt K, Hayoz S, Mc Laughlin A, Kloft C, Klose M, Halbherr S, Baumgartner C, Sessa C, Stathis A, Hess D, Jörger M. TLD-1, a novel liposomal doxorubicin, in patients with advanced solid tumors: Dose escalation and expansion part of a multicenter open-label phase I trial (SAKK 65/16). Eur J Cancer 2024; 201:113588.
Feb 2, 2024TLD-1, a novel liposomal doxorubicin, in patients with advanced solid tumors: Dose escalation and expansion part of a multicenter open-label phase I trial (SAKK 65/16).
Feb 2, 2024Eur J Cancer 2024; 201:113588
Colombo Ilaria, Koster Kira-Lee, Holer Lisa, Haefliger Simon, Rabaglio-Poretti Manuela, Bastian Sara, Schwitter Michael, Eckhardt Katrin, Hayoz Stefanie, Mc Laughlin Anna M, Kloft Charlotte, Klose Marian, Halbherr Stefan, Baumgartner Christian, Sessa Cristiana, Stathis Anastasios, Hess Dagmar, Jörger Markus
Darolutamide Maintenance in Patients With Metastatic Castration-Resistant Prostate Cancer With Nonprogressive Disease After Taxane Treatment (SAKK 08/16).
Gillessen S, Procopio G, Hayoz S, Kremer E, Schwitter M, Caffo O, Lorente D, Pedrazzini A, Roubaud G, Nenan S, Omlin A, Buttigliero C, Delgado Mingorance J, González-Del-Alba A, Delgado M, Nolè F, Turco F, Mestre R, Ribi K, Cathomas R. Darolutamide Maintenance in Patients With Metastatic Castration-Resistant Prostate Cancer With Nonprogressive Disease After Taxane Treatment (SAKK 08/16). J Clin Oncol 2023; 41:3608-3615.
Feb 8, 2023Darolutamide Maintenance in Patients With Metastatic Castration-Resistant Prostate Cancer With Nonprogressive Disease After Taxane Treatment (SAKK 08/16).
Feb 8, 2023J Clin Oncol 2023; 41:3608-3615
Gillessen Silke, Procopio Giuseppe, Hayoz Stefanie, Kremer Eloïse, Schwitter Michael, Caffo Orazio, Lorente David, Pedrazzini Augusto, Roubaud Guilhem, Nenan Soazig, Omlin Aurelius, Buttigliero Consuelo, Delgado Mingorance Juan Ignacio, González-Del-Alba Aránzazu, Delgado Maria Teresa, Nolè Franco, Turco Fabio, Mestre Ricardo Pereira, Ribi Karin, Cathomas Richard
SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2
Mark M, Früh M, Biaggi-Rudolf C, Weindler S, Baudoux N, Schwitter M, Wannesson L, Jörger M, Metaxas Y, Schneider M, Friedlaender A, Burmeister H, Janthur W, Rothschild S, Pless M, Addeo A, Eboulet E, Froesch P, Swiss Group for Clinical Cancer Research (SAKK). SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2. Cancer Immunol Immunother 2020
Nov 1, 2020SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2
Nov 1, 2020Cancer Immunol Immunother 2020
Mark Michael, Früh Martin, Biaggi-Rudolf Christine, Weindler Susanne, Baudoux Nathalie, Schwitter Michael, Wannesson Luciano, Jörger Markus, Metaxas Yannis, Schneider Martina, Friedlaender Alex, Burmeister Henning, Janthur Wolf-Dieter, Rothschild Sacha I, Pless Miklos, Addeo Alfredo, Eboulet Eric Innocents, Froesch Patrizia, Swiss Group for Clinical Cancer Research (SAKK)
Epidermal Growth Factor Receptor Mutation in a Patient with Squamous Cell Carcinoma of the Lung: Who Should Be Tested?
Schwitter M, Früh M, Schneider T, Kluckert J, Rodriguez R, Brutsche M. Epidermal Growth Factor Receptor Mutation in a Patient with Squamous Cell Carcinoma of the Lung: Who Should Be Tested?. Oncology 2013; 2013:263-268.
May 14, 2013Epidermal Growth Factor Receptor Mutation in a Patient with Squamous Cell Carcinoma of the Lung: Who Should Be Tested?
May 14, 2013Oncology 2013; 2013:263-268
Schwitter Michael, Früh Martin, Schneider Tino, Kluckert Jörg-Thomas, Rodriguez Regulo, Brutsche Martin
Epidermal growth factor receptor mutation in a patient with squamous cell carcinoma of the lung: who should be tested?
Schwitter M, Rodriguez R, Schneider T, Kluckert T, Brutsche M, Früh M. Epidermal growth factor receptor mutation in a patient with squamous cell carcinoma of the lung: who should be tested?. Case Rep Oncol 2013; 6:263-8.
May 14, 2013Epidermal growth factor receptor mutation in a patient with squamous cell carcinoma of the lung: who should be tested?
May 14, 2013Case Rep Oncol 2013; 6:263-8
Schwitter Michael, Rodriguez Regulo, Schneider Tino, Kluckert Thomas, Brutsche Martin, Früh Martin